Related Experiment Videos
Hereditary angioedema: a study of three families
J Pola1, R Valdivieso, C Zapata
1Servicio de Alergia, Hospital Ramon y Cajal, Madrid, Spain.
Insights
Familial angioedema, a hereditary C1 inhibitor (C1 INH) deficit, presents varied symptoms. Treatment with stanozolol effectively controlled symptoms, suggesting therapy should focus on patient asymtomaticity rather than C1 INH levels.
Area of Science:
- Genetics
- Immunology
- Hereditary diseases
Background:
- Familial angioedema is an autosomal dominant disorder caused by C1 inhibitor (C1 INH) deficiency or dysfunction.
- Two genetic forms are recognized, impacting C1 INH levels or function.
Observation:
- Studies in three families with C1 INH deficit revealed variable symptomatology among affected members.
- No significant differences in C1 INH levels were found between symptomatic and asymptomatic individuals within these families.
- Absence of family history does not rule out genetic predisposition, as mutations may have been clinically silent in prior generations.
Findings:
- Stanozolol demonstrated efficacy in managing symptoms in two patients with C1 INH deficit.
- While symptoms improved, a significant rise in C1 INH levels was observed in only one patient.
- Clinical improvement did not consistently correlate with normalization of C1 INH levels.
Implications:
- Therapeutic strategies for familial angioedema should prioritize achieving and maintaining patient asymtomaticity.
- Focusing on symptom control with minimal effective medication doses may be more beneficial than solely normalizing C1 INH levels.
- Further research is needed to understand the variable clinical manifestations and guide optimal treatment approaches.
Abstract:
Familial angioedema is an autosomal dominant hereditary disease whose pathogenesis is attributed to a C1 inhibitor (C1 INH) deficit. Two genetic forms have been recognized related to the C1 inhibitor deficiency or its dysfunction. Antifibrinolytics as well as androgenic derivatives have proved to be effective in the prevention and treatment of this pathology. In this paper we present the studies carried out in three families affected by C1 inh. deficit and the treatment employed. Some of the members of these families showed symptoms related with this deficit. A satisfactory explanation has not been formulated to justify the reason why only some of the members in our study showed symptomatology, given that there were no differences between the C1 inh. levels in these patients and those who were not affected. The absence of family history connected with this disease does not necessarily suggest that a genetic mutation has been produced. This deficit could have been present in earlier generations but without clinical manifestations. Stanozolol proved effective in the control of symptoms in the two patients to whom this treatment was applied. However, the rise of C1 inh. levels was significative only in one of them. The lack of connection between the clinical improvement and the normalization of the C1 inh. levels led us to think that the main goal of the therapy should not be directed to the normalization of these levels but to keep the patient asymptomatic with the lowest possible doses of the selected medication.